glimepiride has been researched along with Kidney Diseases in 5 studies
glimepiride: structure given in first source
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mean composite kidney disease progression occurred in 135 (10." | 3.30 | Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. ( Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N, 2023) |
| " Pharmacokinetic data on sulfonylureas are generally inconsistent in cirrhotic patients." | 2.39 | Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. ( Rosenkranz, B, 1996) |
| "The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups." | 1.46 | Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. ( Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y, 2017) |
| "The Cardiff Model was used to simulate disease progression and estimate the long-term effect of treatments on patients." | 1.42 | Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. ( Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L, 2015) |
| "Severe hypoglycemia was defined as a symptomatic event requiring treatment with intravenous glucose and was confirmed by a blood glucose measurement of < 50 mg/dl." | 1.36 | Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. ( Hahn, M; Hammer, C; Holstein, A; Kovacs, P; Kulamadayil, NS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wexler, DJ | 1 |
| de Boer, IH | 1 |
| Ghosh, A | 1 |
| Younes, N | 1 |
| Bebu, I | 1 |
| Inzucchi, SE | 1 |
| McGill, JB | 1 |
| Mudaliar, S | 1 |
| Schade, D | 1 |
| Steffes, MW | 1 |
| Tamborlane, WV | 1 |
| Tan, MH | 1 |
| Ismail-Beigi, F | 1 |
| Gu, S | 1 |
| Deng, J | 1 |
| Shi, L | 1 |
| Mu, Y | 1 |
| Dong, H | 1 |
| Desai, M | 1 |
| Yavin, Y | 1 |
| Balis, D | 1 |
| Sun, D | 1 |
| Xie, J | 1 |
| Canovatchel, W | 1 |
| Rosenthal, N | 1 |
| Holstein, A | 1 |
| Hammer, C | 1 |
| Hahn, M | 1 |
| Kulamadayil, NS | 1 |
| Kovacs, P | 1 |
| Rosenkranz, B | 1 |
1 review available for glimepiride and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Di | 1996 |
1 trial available for glimepiride and Kidney Diseases
| Article | Year |
|---|---|
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Ra | 2023 |
3 other studies available for glimepiride and Kidney Diseases
| Article | Year |
|---|---|
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analy | 2015 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration | 2017 |
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Comorbidity; Diabetes Mellitus, | 2010 |